Alnylam Pharmaceuticals Q3 Adj $1.74 Beats $(1.47) Estimate, Sales $750.53M Beat $383.54M Estimate
Portfolio Pulse from Benzinga Newsdesk
Alnylam Pharmaceuticals reported Q3 earnings of $1.74 per share, beating the analyst consensus estimate of $(1.47) by 218.37%. The company also reported quarterly sales of $750.53 million, beating the analyst consensus estimate of $383.54 million by 95.68%. This represents a 210.13% increase in earnings and a 183.96% increase in sales compared to the same period last year.
November 02, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alnylam Pharmaceuticals reported significantly higher Q3 earnings and sales than expected, which could positively impact its stock price.
Alnylam Pharmaceuticals reported Q3 earnings and sales that significantly exceeded analyst estimates. This strong financial performance could increase investor confidence and drive up the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100